Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 23;6(11):1997–2008. doi: 10.1002/sctm.17-0091

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Stromal cell‐derived factor‐1 (SDF‐1) mediates ERC‐based therapy in increasing the percentage of both regulatory T cell (Tregs) and regulatory B cell (Bregs) in allograft recipients. Splenocytes were collected from B6 recipients in each group at postoperative day 8. For the Tregs, the percentage of CD25⁺Foxp3⁺ cells in CD4⁺ gating population was determined by fluorescence‐activated cell sorting analysis. (A): Dot plots of CD4⁺CD25⁺Foxp3⁺ T cells. (B): Percentage of CD4⁺CD25⁺Foxp3⁺ T cells. For the Bregs, the percentage of CD83⁺ (C), CD1d⁺CD5⁺ (D), or IL‐10⁺ (E) cells in CD19⁺ gating population was measured. *ERCs indicated inhibition the function of SDF‐1 by AMD3100. Statistical analysis was done by one‐way analysis of variance followed by the least significant difference test, n = 6. Abbreviations: ERC, endometrial regenerative cell; RAPA, rapamycin.